<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03286829</url>
  </required_header>
  <id_info>
    <org_study_id>TM003</org_study_id>
    <nct_id>NCT03286829</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Pharmacokinetic Profile</brief_title>
  <official_title>A Randomized, Open-label, Single-dose, Parallel-arm, Phase 1 Study to Investigate the Pharmacokinetic Profile of a Fixed-Dose Combination Tablet of Tesofensine and Metoprolol (Tesomet) and Co-Administration of Tesofensine Plus Commercial Metoprolol in Adult Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Saniona</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Saniona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, open-label, single-dose, parallel-arm, Phase 1 study to investigate the
      pharmacokinetic profile of a fixed-dose combination tablet of tesofensine and metoprolol
      (Tesomet) and co-administration of tesofensine plus commercial metoprolol in adult healthy
      subjects
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, open-label, parallel-arm study in 60 healthy male subjects who meet the
      inclusion and none of the exclusion criteria for the study. Each subject will participate in
      a screening period, a baseline period (the day preceding drug administration), and a
      single-dose treatment period with an on-site observation period of at least 48 hours after
      the dose.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 18, 2017</start_date>
  <completion_date type="Actual">February 6, 2018</completion_date>
  <primary_completion_date type="Actual">February 6, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-48</measure>
    <time_frame>48 hours</time_frame>
    <description>Area under the concentration-time curve from pre-dose (time 0) to 48 hours post-dose calculated using the linear-log trapezoidal rule</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>48 hours</time_frame>
    <description>Maximum tesofensine and metoprolol concentrations determined directly from the concentration-time profile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>48 hours</time_frame>
    <description>Time of maximum tesofensine and metoprolol concentrations determined directly from the concentration-time profile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz</measure>
    <time_frame>48 hours</time_frame>
    <description>he terminal elimination rate constant determined by selection of at least three data points on the terminal phase of the concentration-time curves</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t½</measure>
    <time_frame>48 hours</time_frame>
    <description>Terminal elimination half-life calculated as: ln2/λz</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Healthy Male Subjects</condition>
  <arm_group>
    <arm_group_label>Treatment A (Test 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment A (Test 1): A Tesomet FDC tablet (20 mg immediate release [IR] metoprolol, 1 mg tesofensine, 80 mg extended release [ER] metoprolol) in fasted condition (&quot;High&quot; dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B (Test 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment B (Test 2): A Tesomet FDC tablet (5 mg immediate IR metoprolol, 0.2 mg tesofensine, 20 mg ER metoprolol) in fasted condition. (&quot;Low&quot; dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C (Comparator)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment C (Comparator): 1 mg tesofensine (2 tablets of 0.5 mg), 25 mg commercial IR metoprolol (1 tablet of 25 mg), 75 mg commercial ER metoprolol (1 tablet of 25 mg ER metoprolol and 1 tablet of 50 mg ER metoprolol), fasted condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D (Test 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment D (Test 3): A Tesomet FDC tablet (20 mg immediate IR metoprolol, 1 mg tesofensine, 80 mg ER metoprolol in fed condition (&quot;High&quot; dose)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tesomet &quot;High dose&quot; in fasted condition</intervention_name>
    <description>To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.</description>
    <arm_group_label>Treatment C (Comparator)</arm_group_label>
    <arm_group_label>Treatment D (Test 3)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tesomet &quot;Low dose&quot; in fasted condition</intervention_name>
    <description>To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.</description>
    <arm_group_label>Treatment C (Comparator)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comperator 1 mg tesofensine, 25 mg commercial IR metoprolol, 75 mg commercial ER metoprolol, fasted condition.</intervention_name>
    <description>To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.</description>
    <arm_group_label>Treatment A (Test 1)</arm_group_label>
    <arm_group_label>Treatment B (Test 2)</arm_group_label>
    <arm_group_label>Treatment D (Test 3)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tesomet &quot;High dose&quot; in fed condition</intervention_name>
    <description>To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.</description>
    <arm_group_label>Treatment C (Comparator)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject voluntarily agrees to participate in this study and signs an Independent
             Ethics Committee (IEC)-approved informed consent prior to performing any of the
             Screening Visit procedures.

          2. Males between 18 to 55 years of age, inclusive, at the Screening Visit.

          3. Nonsmokers (or other nicotine use) as determined by history (no nicotine use over the
             past 6 months) and by urine cotinine concentration (&lt; 500 ng/mL) at the Screening
             Visit and admission.

          4. BMI between 18.5 and 30.0 kg/m2, inclusive, at the Screening Visit.

          5. Healthy, determined by pre-study medical evaluation (medical history, physical
             examination, vital signs, 12-lead ECG and clinical laboratory evaluations).

        Exclusion Criteria:

          1. Subject has history or evidence of any clinically significant cardiovascular,
             gastrointestinal, endocrinologic, hematologic, hepatic, immunologic, metabolic,
             urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other major
             disease or malignancy as judged by the Investigator.

          2. Subject has any disorder that would interfere with the absorption, distribution,
             metabolism or excretion of drugs.

          3. Subject has history of alcohol and/or illicit drug abuse within 2 years of entry.

          4. Subject is unwilling to avoid consumption of coffee and caffeine-containing beverages
             within 48 hours prior to admission until discharge from the clinical site.

          5. Subject is unwilling to avoid use of alcohol or alcohol-containing foods, medications
             or beverages, within 48 hours prior to admission until discharge from the clinical
             site.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roman Dvorak, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Saniona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Early Phase Clinical Unit;Klinikum Westend, Haus 31</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2017</study_first_submitted>
  <study_first_submitted_qc>September 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 19, 2017</study_first_posted>
  <last_update_submitted>April 4, 2018</last_update_submitted>
  <last_update_submitted_qc>April 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metoprolol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

